# Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

> **NCT03852628** · PHASE2 · TERMINATED · sponsor: **Pharmacotherapies for Alcohol and Substance Use Disorders Alliance** · enrollment: 69 (actual)

## Conditions studied

- Post Traumatic Stress Disorder
- Alcohol Abuse

## Interventions

- **DRUG:** 2mg Buprenex and 380mg Vivitrol
- **DRUG:** Placebo (SL pill qd, IM injection q4weeks)

## Key facts

- **NCT ID:** NCT03852628
- **Lead sponsor:** Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-20
- **Primary completion:** 2022-05-02
- **Final completion:** 2023-01-30
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** Futility analysis
- **Last updated:** 2023-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852628, "Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03852628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*